JP2011525506A - 心不全を処置するためのジアリールウレア類 - Google Patents

心不全を処置するためのジアリールウレア類 Download PDF

Info

Publication number
JP2011525506A
JP2011525506A JP2011515168A JP2011515168A JP2011525506A JP 2011525506 A JP2011525506 A JP 2011525506A JP 2011515168 A JP2011515168 A JP 2011515168A JP 2011515168 A JP2011515168 A JP 2011515168A JP 2011525506 A JP2011525506 A JP 2011525506A
Authority
JP
Japan
Prior art keywords
formula
heart failure
inhibitor
alkyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011515168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525506A5 (enExample
Inventor
バルバラ・アルブレヒト−キュッパー
シュテファン・シェファー
エロディエ・キエンラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of JP2011525506A publication Critical patent/JP2011525506A/ja
Publication of JP2011525506A5 publication Critical patent/JP2011525506A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011515168A 2008-06-25 2009-06-18 心不全を処置するためのジアリールウレア類 Withdrawn JP2011525506A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08011471 2008-06-25
EP08011471.3 2008-06-25
PCT/EP2009/004390 WO2009156089A1 (en) 2008-06-25 2009-06-18 Diaryl ureas for treating heart failure

Publications (2)

Publication Number Publication Date
JP2011525506A true JP2011525506A (ja) 2011-09-22
JP2011525506A5 JP2011525506A5 (enExample) 2012-11-08

Family

ID=41136709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011515168A Withdrawn JP2011525506A (ja) 2008-06-25 2009-06-18 心不全を処置するためのジアリールウレア類

Country Status (13)

Country Link
US (1) US20110263657A1 (enExample)
EP (1) EP2293792A1 (enExample)
JP (1) JP2011525506A (enExample)
KR (1) KR20110031294A (enExample)
CN (1) CN102076338A (enExample)
AU (1) AU2009262599A1 (enExample)
BR (1) BRPI0914636A2 (enExample)
CA (1) CA2729050A1 (enExample)
IL (1) IL209647A0 (enExample)
MX (1) MX2010014441A (enExample)
RU (1) RU2011102471A (enExample)
WO (1) WO2009156089A1 (enExample)
ZA (1) ZA201009063B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102718703B (zh) * 2011-03-31 2016-09-14 中国医学科学院药物研究所 Gk和ppar双重激动活性的含有二甲基的芳基脲类衍生物
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
AP2013007331A0 (en) 2011-06-24 2013-12-31 Amgen Inc TRPM8 antagonists and their use in treatments
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
RU2646454C2 (ru) * 2013-11-12 2018-03-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Способ моделирования алкогольной кардиомиопатии

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) * 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
WO2007087575A2 (en) * 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
WO2009092442A1 (en) * 2008-01-23 2009-07-30 Universidad De Barcelona Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways

Also Published As

Publication number Publication date
AU2009262599A1 (en) 2009-12-30
IL209647A0 (en) 2011-02-28
KR20110031294A (ko) 2011-03-25
MX2010014441A (es) 2011-01-21
BRPI0914636A2 (pt) 2015-10-20
ZA201009063B (en) 2012-02-29
US20110263657A1 (en) 2011-10-27
CN102076338A (zh) 2011-05-25
CA2729050A1 (en) 2009-12-30
EP2293792A1 (en) 2011-03-16
WO2009156089A1 (en) 2009-12-30
RU2011102471A (ru) 2012-07-27

Similar Documents

Publication Publication Date Title
JP5075832B2 (ja) 肺高血圧を処置するためのジアリールウレア
JP7101688B2 (ja) ｓＧＣ刺激薬とミネラルコルチコイド受容体拮抗薬とを含む組み合わせ
US20120029002A1 (en) Benzimidazole and pyrazolopyridine derivatives for treating and/or preventing cardiovascular diseases
US11331308B2 (en) Combination containing sGC activators and mineralocorticoid receptor antagonists
CN104703964A (zh) 取代氨基茚满-和氨基萘满甲酸及其用途
TWI667234B (zh) 經取代之六氫吡啶基四氫喹啉
JP2009536929A (ja) ３−テトラゾリルインダゾール類および３−テトラゾリルピラゾロピリジン類並びにそれらの使用
JP5084736B2 (ja) 肺高血圧を処置するためのジアリールウレア
US20110263657A1 (en) Diaryl ureas for treating heart failure
JP2011525503A (ja) 心不全を処置するためのジアリールウレア
CA3120775A1 (en) Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
JP2025502842A (ja) 薬学的に活性な化合物としての使用のための（５ｓ）－｛［２－（４－カルボキシフェニル）エチル］［２－（２－｛［３－クロロ－４’－（トリフルオロメチル）ビフェニル－４－イル］メトキシ｝フェニル）エチル］アミノ｝－５，６，７，８－テトラヒドロキノリン－２－カルボン酸及びその結晶形態を調製するための方法
WO2017029261A1 (de) Kombinationspräparat umfassend finerenone und einen nep-inhibitor (sacubitril)
HK1157683A (en) Diaryl ureas for treating heart failure
ES2356931T3 (es) Diaril ureas para tratar la hipertensión pulmonar.
JP2009514920A (ja) 糖尿病性神経障害を処置するためのジアリールウレア
RU2431484C2 (ru) Диарилмочевина для лечения легочной гипертензии

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120924

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20121225